Cell Viability Assays Market is Segmented By Product (Consumables (Reagents, Assay Kits), Tetrazolium Reduction Assay Kits, Resazurin Cell Viability Assay Kits, Calcein-AM Cell Viability Assay Kits, Microplates, Spectrophotometers, Flow Cytometers, Automated Cell Counters, Cell Imaging & Analysis Systems), By Cell Type (Human Cell, Microbial Cells, Animal Cells), By Application (Stem Cell Research, Drug Discovery, and Development, Basic Research, Others), By End-user (Hospital and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Cell Viability Assays Market Overview
Cell Viability Assays Market size was valued USD YY million in 2024 and is estimated to reach USD YY million by 2031, growing at a CAGR of 14% during the forecast period (2024-2031).
Cell Viability Assays Market Scope
Metrics |
Details |
Market CAGR |
14% |
Segments Covered |
By Product, By Cell Type, By Application, By By End-User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
To Get a Free Sample Click here
Cell viability assays are a technique for determining the overall health of cells and determining the properties of cell survival. It is a homogenous approach for determining the quantity of dead or surviving cells in a sample, regardless of the cell cycle phase. The total live/total cells ratio determines the cell viability assay. Cell viability that increases implies cell proliferation, while cell viability that decreases suggests harmful consequences of the substance.
Market Dynamics
The Novel approaches for cytotoxicity assessment are expected to drive market growth.
The current tendency is to lower the number of necessary cells and analysis time while boosting screening capability and assay accuracy and sensitivity with single-cell resolution in mind. Microfabrication and surface engineering provide revolutionary cytotoxicity assessment methodologies with great sensitivity and the ability to automate to reduce user participation. When it comes to specific cytotoxic measurements or information that cannot be obtained with traditional assays, such as cytotoxicity dynamics, real-time monitoring, gradient formation, and multiplexing; or information that can be obtained easily and faster than with traditional tools, such as single-cell testing or combinatorial testing, the use of the micro platform for cytotoxicity testing is very useful right now. On the other hand, microtechnology appears to have a place in cytotoxicity assessment. It has recently gained importance and popularity, as seen by the growing number of articles with novel methodologies. Moreover, new advances in this field are predicted to focus on improving device manufacturing, streamlining methods for potential mass production, and seeking suitable materials with features that allow for high analysis performance. As a result, research suggests that advances in microtechnology will significantly impact the future of cytotoxicity testing.
Restraint:
The high cost of instruments for cell viability and the lack of professionals and technical experts to run these instruments are the major factors the market is expected to get hampered in the forecast period.
Industry Analysis
The cell viability assays market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The study of SARS-CoV-2 infection and evaluating different anti-SARS-CoV-2 drugs needed extremely limited BSL-3 containment since SARS-CoV-2 is designated as an aerosol biosafety level 3 (BSL-3) pathogen. Understanding the SARS-CoV-2 virus's infection routes, virus-host–protein interactions, and mechanisms of virus-induced cytopathic effects can aid in the discovery and development of novel COVID-19 treatments. The CPE reduction test is a commonly used antiviral drug screening format that may be scaled up for high-throughput screening. The viral infection causes host cell death in this assay, and cell viability is a surrogate readout for a viral infection that may be evaluated using a variety of cell viability assays.
Moreover, to find compounds that exerted cytotoxicity against Vero E6 cells, all compounds are evaluated against cells that had not been exposed to the virus as a counter experiment. Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Therefore, SARS-CoV-2-related research in microbiology laboratories has been severely hampered due to this situation. Thus, the COVID-19 pandemic has affected the market.
Segment Analysis
Consumables segment is expected to hold the largest market share in cell viability assays market
The consumables segment accounted for the largest market share in 2021. Reagents, test kits, and microplates are the three types of consumables. Tetrazolium reduction assay kits, comforting cell viability test kits, calcien- AM cell viability assay kits, and other assay kits are among the subcategories of assay kits. Instruments were further subdivided into automated cell counters, flow cytometers, spectrophotometers, cell imaging and analysis systems, etc. The segmented is benefited because MTT assay includes ease and rapidity of performance, reproducibility of the results and observed clinical correlation between in vitro and in vivo testing. For instance, A 96-well plate reader can detect as low as 1,000 cells per well in the CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT). The neutral red assay technique has a lower sensitivity. It is utilized with a wide range of cells for testing, including mammalian, plant, and yeast cells. There is no need for a scintillation cocktail or radioactive waste disposal, and the assay can be done in a 96-well plate with no washing, cell harvesting, or scintillation counting. Furthermore, it follows a 4-hour or overnight approach and does not involve weighing or mixing dye components. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Geographical Analysis
North America region holds the largest market share in the global cell viability assays market
North America accounted for the largest market share in 2021. The increasing prevalence of various neurodegenerative diseases, high-quality clinical and laboratory research facilities, rise in government investment initiatives, presence of well-established infrastructure, rising healthcare and R&d expenditure and availability of insurance of coverage for the laboratory testing procedures in the region are some of the factors the market is expected to boost in the forecast period. For instance, several neurodegenerative diseases and congenital neural anomalies are characterized by excessive cell death, and autoimmune diseases can result from stimulating T cells by apoptotic fragments resulting from chronic inflammation or failure of the immune system to down-regulate after stimulation. According to the Alzheimers Association, More than 6 million Americans live with Alzheimer's, and by 2050, this number is projected to rise to nearly 13 million. 1 in 3 seniors dies with Alzheimer's or another dementia.
Moreover, in 2020, COVID-19 contributed to a 17% increase in Alzheimer's and dementia deaths, and more than 11 million Americans provide unpaid care for people with Alzheimer's or other dementias. Therefore, insurance coverage for the laboratory testing procedures and demand for cell viability assays increased. Thus, the North American region is expected to hold the largest market share in the forecast period.
Competitive Landscape
Major key players in the cell viability assays market are Thermo Fischer Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Becton Dickinson & Company, Abcam PLC, Tip Biosystems Pte Ltd, ACROBiosystems, Biotek Instruments, Perkinelmer and Promega Corporation.
Thermo Fisher Scientific:
Overview:
Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Product Portfolio:
CyQUANT MTT Cell Viability Assay: CyQUANT MTT is a well-established and popular colorimetric assay that determines cell viability using the cellular redox potential in live cells. Metabolically active cells convert the water-soluble MTT reagent to an insoluble purple formazan product detected on a microplate reader by measuring absorbance at 570 nm.
The global cell viability assays market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
